Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
May 10, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
May 09, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
April 30, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Receives $225 Million Milestone Payment from Ipsen
March 27, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Full Year 2023 Financial Results
March 07, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
February 13, 2024
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports First Quarter 2023 Financial Results
May 04, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Full Year 2022 Financial Results
March 09, 2023
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
December 05, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
November 09, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Merrimack Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
August 03, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports First Quarter 2022 Financial Results
May 05, 2022
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Third Quarter 2021 Financial Results
November 04, 2021
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Merrimack Reports Second Quarter 2021 Financial Results
August 05, 2021
From
Merrimack Pharmaceuticals, Inc.
Via
Business Wire
Tickers
MACK
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.